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Abstract
Of 400 patients with hilar cholangiocarcinoma who were treated at Nagoya University Hospital from 1977 to 2004, 301 (75%)
underwent surgical resection. Most patients underwent major hepatectomy with extrahepatic bile duct resection. The overall
mortality rate was 7.6% but had decreased to 2.5% in the last 5 years (p=0.007). The overall survival rates at 5, 10 and 15
years were 22%, 13% and 10%, respectively. The survival rates of 233 patients undergoing R0 resection were 27%, 16% and
13%, respectively. R1 or R2 resection, lymph node metastasis and portal vein involvement were significant negative prognostic
factors, although survival was better than in patients with unresected tumours. The results show that aggressive surgical
treatment of hilar cholangiocarcinoma offers good outcomes with an acceptable mortality rate.
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Introduction
Although many articles have been published regarding
hilar cholangiocarcinoma, the resection rate of this
intractable disease is still low in most centres.
Aggressive surgery to achieve a curative resection can
offer a better survival than conservative therapy [1–3].
Precise preoperative evaluation of tumour extent is
mandatory to plan a curative resection, and hepatect-
omy with caudate lobe resection is necessary in most
cases [4]. Concomitant portal vein resection and
reconstruction have been applied to increase the
resection rate and to prolong patients’ survival
[1,2,5–7]. Still controversial, however, is the issue of
combining pancreatoduodenectomy and major liver
resection in the treatment of hilar cholangiocarcinoma
[8]. We have treated patients with hilar cholangiocar-
cinoma following an aggressive strategy and herein
describe the results of our 27 years of experience at the
Nagoya University Hospital.
Patients and surgical indications
From 1977 to 2004, 400 patients with hilar cholangio-
carcinoma were treated at the Nagoya University
Hospital and were included in this study. There were
259 males and 141 females, with an average age of 62
years (range 24–84 years).
Exclusion criteria for surgical resection are lung
metastasis, peritoneal dissemination, perineural inva-
sion around the common hepatic artery and liver
metastasis in the future liver remnant. When the
tumour extends along the intrahepatic bile ducts
proximally to both the umbilical fissure and the
confluence of the right posterior superior and inferior
segmental ducts, surgery is not attempted. In all other
cases, aggressive surgery is planned.
Most patients presented with obstructive jaundice
and underwent percutaneous transhepatic biliary
drainage (PTBD). PTBD encompassed all occluded
biliary branches of all hepatic segments except the
caudate lobe, to establish precise diagnosis of proximal
tumour involvement and to relieve jaundice. Recently,
PTBD has only been applied to the bile ducts of
hepatic segments which will be preserved. It may be
performed in second intention in isolated bile ducts in
cases of segmental cholangitis, insufficient biliary
drainage and/or insufficient cholangiography preclud-
ing precise diagnosis of tumour extent. Major hepa-
tectomy is performed only after serum total bilirubin
level has decreased to below 2 mg/dl.
Categorical variables were compared by the Fisher’s
exact test. Long-term survival was calculated using the
Kaplan–Meier method and compared using the log-
rank test. A p value50.05 was considered statistically
significant.
Results
Of the 400 patients, 301 (75%) underwent surgical
resection. Operative procedures are shown in Table I.
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Most patients underwent major hepatectomy with
extrahepatic bile duct resection. Surgical techniques
and perioperative management have obviously
improved throughout the years. Therefore, the mor-
tality rate in the last 5 years is significantly better than
that during the preceding 20 years (3/117 vs 20/184,
p=0.007) (Table II). The overall survival rates at 5, 10
and 15 years for the 301 patients undergoing surgical
resection were 22%, 13% and 10%, respectively
(Figure 1). Overall median survival was 2.0 years.
Survival rates of 233 patients undergoing R0 resection
were 27%, 16% and 13%, respectively, with a median
survival of 2.3 years (Figure 2). Patients without lymph
node metastasis survived significantly longer than
those with lymph node metastasis (Figure 3). However,
8 of the 149 patients with positive lymph node
metastasis survived45 years. Patients who underwent
combined portal vein resection survived for a signifi-
cantly shorter time than those who did not need portal
vein resection (Figure 4). Six of the 97 patients
undergoing combined portal vein resection and recon-
struction survived45 years. Survival times of patients
with lymph node metastasis and/or portal vein resec-
tion were significantly better than those of unresected
patients.
Discussion
We have performed aggressive surgery for patients with
hilar cholangiocarcinoma and obtained good out-
comes. There are 38 5-year survivors in the R0
resection group resulting in a 27% 5-year survival
rate. Of 80 patients without cancer invasion of the
portal vein nor regional lymph node metastasis, 23
survived 45 years after R0 resection and the 5-year
survival rate was 50% [9]. Lymph node micro-
metastasis has no impact on survival in patients with
otherwise negative lymph nodes, whereas extended
lymph node dissection may provide a survival benefit
in patients with hilar cholangiocarcinoma [10,11].
Table I. Surgical procedures performed in 301 consecutive patients
resected for hilar cholangiocarcinoma (1977–2004)
Procedures
No. of
patients With PV With PD
BDR only 16 3 4
Hepatectomy+BDR 285 94 28
S1,4,5,6,7,8 22 11 2
S1,5,6,7,8+S4a 89 34 17
S1,2,3,4,5,8 34 12 2
S1,2,3,4 108 33 1
S1,4,5,8 11 3 1
Others 21 1 5
Total 301 97 (32%) 32 (11%)
PV, portal vein resection; PD, pancreatoduodenectomy; BDR, bile
duct resection; S4a, inferior part of the left medial hepatic segment.
Note that one patient in category “S1,2,3,4” did not undergo
caudate lobe resection because all of the biliary branches from the
caudate lobe could be preserved.
Table II. Incidence of liver failure and mortality among 301 patients
resected for hilar cholangiocarcinoma
Time period No. of resected patients Liver failure Mortality
1977–1989 60 9 (15%) 8 (13%)
1990–1994 55 16 (29%) 4 (7%)
1995–1999 69 15 (22%) 8 (12%)
2000–2004 117 7 (6%) 3 (2.5%)
Total 301 47 (16%) 23 (7.6%)
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Figure 1. Overall survival curves of patients who underwent resection for hilar cholangiocarcinoma (1977–2004). MST, median survival
time.
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Although lymph node metastasis and macroscopic
portal vein involvement were independent negative
prognostic factors in multivariate analysis of our
recent series [12], the 5-year survival rate obtained in
patients with portal vein resection or lymph node
metastasis still was about 10%. Even in patients with
both cancer invasion of the portal vein and regional
lymph node metastasis, or with para-aortic lymph node
metastasis, curative resection resulted in significantly
longer survival than that found in unresected patients
[9,10].
As surgical techniques and perioperative manage-
ment have improved, resection can be performed more
safely than before even though our surgical strategy has
become more aggressive. During the past 5 years, our
mortality rate was 55%. It still remains controversial
whether radiotherapy and/or chemotherapy with/with-
out tumour resection can prolong survival of patients
with hilar cholangiocarcinoma [13,14].
In conclusion, aggressive surgery for hilar cholan-
giocarcinoma can offer good outcomes with an
acceptable mortality rate. These findings may
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Figure 2. Survival curves according to completeness of resection. R0, microscopically radical resection; R1, macroscopically radical
resection; R2, macroscopically non-radical resection.
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Figure 3. Survival curves according to the presence of lymph node metastasis (LNM).
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encourage surgeons to follow an aggressive strategy in
surgical treatment for hilar cholangiocarcinoma.
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Figure 4. Survival curves according to portal vein resection. PVR, portal vein resection and reconstruction.
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